Child Protection Resource - 8 October 2020

Child Protection Resource - 10 September 2020 - Sarah Phillimore

Can science ever debate trans issues?

UnHerd - June 3 2020 - Jesse Singal

Over the last few years, there’s been an explosion of awareness about the condition known as gender dysphoria — a sense of deep, painful discomfort with one’s biological sex, the gender associated with it, or both. Gender dysphoria can cause devastating anguish when the person suffering from it lacks access to treatment.

Another unfortunate experiment? New Zealand’s transgender health policy and its impact on children

Speak Up For Women - 11 August 2020 - Jan Rivers and Jill Abigail

Tavistock’s Experimentation with Puberty Blockers: Scrutinizing the Evidence

Transgender Trend - 5 March 2019 - Michael Biggs

The role of the GP in caring for gender-questioning and transgender patients: RCGP Position Statement

Royal College of Physicians UK - June 2019

The significant lack of evidence for treatments and interventions which may be offered to people with dysphoria is a major issue facing this area of healthcare. There are also differences in the types and stages of treatment for patients with gender dysphoria depending on their age or stage of life. Gonadorelin (GnRH) analogues are one of the main types of treatment for young people with gender dysphoria. These have long been used to treat young children who start puberty too early, however less is known about their long-term safety in transgender adolescents. Children who have been on GnRH for a certain period of time and are roughly 16 years of age can be offered cross-sex hormones by the NHS, the effects of which can be irreversible. There is a significant lack of robust, comprehensive evidence around the outcomes, side effects and unintended consequences of such treatments for people with gender dysphoria, particularly children and young people, which prevents GPs from helping patients and their families in making an informed decision.